The concept that a loss of CD44 expression, rather than its overexpression, could signify a more aggressive phenotype is supported by evidence from a large study of 410 primary urothelial bladder cancers, which found that absent CD44v6 expression was an independent predictor of poor outcome. Here, CD44 is linked to bladder transitional cell carcinoma.